For further details see:
Wuxi Biologics acquires drug substance facility from BayerFor further details see:
Wuxi Biologics acquires drug substance facility from BayerMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Fast Track designation follows positive preliminary Phase 2 trial data presented at the European Association for the Study of the Liver Congress 2024 and underscores the unmet need for people living with chronic hepatitis delta Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that ...
2024-06-05 19:15:02 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for VIR on June 5, 2024 05:15PM ET. The previous analyst recommendation was Equal-Weight. VIR was trading at $12.66 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-05 17:00:05 ET Michael Ulz from Morgan Stanley issued a price target of $15.00 for VIR on 2024-06-05 14:37:00. The adjusted price target was set to $15.00. At the time of the announcement, VIR was trading at $12.66. The overall price target consensus is at $30.13...